Table 3.
Selected clinical trials investigating PrEP and PEP for prevention of HIV infection.
| Trial identifier | Status | Phase | Target group | Alternate study ID | Component | Comment/references |
|---|---|---|---|---|---|---|
| PrEP | ||||||
| NCT00458393 | Active | III | MSM | Peru PrEP, iPREX | Emtricitabine/tenofovir disoproxil fumarate | 44% efficacy; Grant et al., 2010 |
| NCT00931346 | Complete | I/II | HIV discordant couples | IAVI E002 | Emtricitabine/tenofovir disoproxil fumarate | – |
| NCT00557245 | Active | III | HIV discordant couples | 32528-A, IND 75,365 | Emtricitabine/tenofovir disoproxil fumarate | – |
| NCT01473472 | Not yet recruiting | III | MSM | IPERGAY | Emtricitabine and tenofovir disoproxil fumarate (truvada) | – |
| NCT01275443 | Recruiting | I | People at risk for HIV | SSAT 040 | TMC278 (rilpivirine), long-acting formulation | – |
| PEP | ||||||
| NCT00594646 | Complete | IV | High-risk sexual contact | MK PEP 2007 | Fixed-dose tenofovir and raltegravir | – |
| NCT00385645 | Complete | IV | Accidental HIV exposure | DATEM-PEP | AZT-3TC + lopinavir-ritonavir vs. ZT-3TC + atazanavir | – |
| NCT01140880 | Recruiting | II | MSM | MC08-LA-710-FRI | Emtricitabine and tenofovir disoproxil fumarate (truvada) | – |
| NCT00949234 | Recruiting | II | High-risk sexual contact | PQUAD | Tenofovir + emtricitabine, lopinavir/ritonavir | – |
| NCT01087840 | Recruiting | IV | MSM | RAL-NPEP | Raltegravir | – |
More information about the individual trials can be found using the NCT number and the following databases: www.aidsinfo.nih.gov/clinical-trials; www.clinicaltrials.gov; http://www.avac.org.